Spetzler David Baxley 4
4 · Caris Life Sciences, Inc. · Filed Jun 23, 2025
Insider Transaction Report
Form 4
Spetzler David Baxley
President
Transactions
- Disposition to Issuer
Common Stock
2025-03-03$18.60/sh−700,509$13,029,467→ 351,240 total - Award
Stock Option
2025-03-03+750,000→ 750,000 totalExercise: $18.60Exp: 2035-03-03→ Common Stock (750,000 underlying) - Award
Common Stock
2025-06-18+132,428→ 483,668 total - Exercise/Conversion
Common Stock
2025-06-20$2.44/sh+75,000$183,000→ 558,668 total - Exercise/Conversion
Stock Option
2025-06-20−75,000→ 0 totalExercise: $2.44Exp: 2025-06-23→ Common Stock (75,000 underlying) - Tax Payment
Common Stock
2025-06-20$27.25/sh−34,782$947,810→ 523,886 total
Footnotes (5)
- [F1]Represents shares of Common Stock surrendered to the Issuer as repayment for an outstanding promissory note.
- [F2]Includes 151,750 shares of Common Stock underlying restricted stock units which vest in accordance with the applicable grant agreements, which securities were previously reported on the Reporting Person's Form 3. All the securities reported in this Form 4 reflect a one-for-four reverse stock split effected as of June 1, 2025.
- [F3]Represents an award of restricted stock units which vest in accordance with the applicable grant agreement.
- [F4]The stock option vested 60% at grant and will vest 20% on August 11, 2025 and 20% on August 11, 2026. These securities were previously reported on the Reporting Person's Form 3.
- [F5]The stock option is fully vested and exercisable.